Analysts expect Immix Biopharma, Inc. to report revenue of 0.00 for Q2 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - | ||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.30 M | ||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.94 M | ||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.12 M |
Analysts expect Immix Biopharma, Inc. to report earnings per share of -0.19 for Q2 26, against a range of -0.20 to -0.18. The most recent reported quarter, Q1 26, came in at -0.18, a 5.3% beat against the -0.19 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.15 | -0.24 | -0.18 | -0.15 | -0.22 | -0.24 | -0.27 | -0.18 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -0.15 | -0.14 | -0.22 | -0.23 | -0.15 | -0.23 | -0.13 | -0.18 | -0.18 | -0.16 | -0.17 | -0.21 | -0.23 | -0.20 | -0.18 | -0.10 | |||||||||||
| Low Estimate | -0.17 | -0.16 | -0.24 | -0.25 | -0.17 | -0.25 | -0.15 | -0.20 | -0.20 | -0.18 | -0.19 | -0.23 | -0.25 | -0.22 | -0.22 | -0.12 | |||||||||||
| Consensus Estimate | -0.16 | -0.15 | -0.23 | -0.24 | -0.16 | -0.24 | -0.14 | -0.19 | -0.19 | -0.17 | -0.18 | -0.22 | -0.24 | -0.21 | -0.20 | -0.11 |